@article {NakamuraPA3767, author = {Junichi Nakamura and Ichizo Tsuzino and Takahiro Sato and Hiroshi Ohira and Satoshi Itaya and Chisa Takashina-Goto and Taku Watanabe and Masaru Suzuki and Satoshi Konno and Masaharu Nishimura}, title = {Amelioration of right ventricular morphology and systolic function in patients with severe group 3 pulmonary hypertension treated with pulmonary vasodilators}, volume = {46}, number = {suppl 59}, elocation-id = {PA3767}, year = {2015}, doi = {10.1183/13993003.congress-2015.PA3767}, publisher = {European Respiratory Society}, abstract = {Background: Recent studies have shown that pulmonary arterial hypertension (PAH)-approved vasodilators improve right ventricular (RV) function in PAH. However, it remains unknown whether PAH-approved drugs also improve RV morphology and function in lung disease-associated pulmonary hypertension (group 3 PH).Aim: To evaluate the RV morphology and systolic function in patients with group 3 PH treated with PAH-approved vasodilators.Methods: Consecutive patients with severe group 3 PH, defined as mean pulmonary arterial pressure >= 35 mmHg or cardiac index \< 2 L/min/m2, were studied. Right heart catheterization and cardiac magnetic resonance imaging were performed at baseline and at 3{\textendash}4 months follow-up, during which the patients received an optimal medical treatment including oxygen plus sildenafil with or without other PAH-approved drug(s).Results: A total of 10 patients were enrolled in the study (mean age, 66 {\textpm}15 years). Their underlying lung diseases were combined pulmonary fibrosis and emphysema (n = 5), interstitial pneumonia (n = 2), chronic obstructive pulmonary disease (n = 2), and cystic lung disease (n = 1). One patient died during the follow-up period. Compared with the baseline data, the follow-up data (n = 9) indicated significant decrease in RV end-diastolic volume index (125 {\textpm} 13 to 96 {\textpm} 7 mL/m2, p = 0.013) and pulmonary vascular resistance (11.8 {\textpm} 1.5 to 7.5 {\textpm}1.0 W.U., p = 0.014), and an increase in RV ejection fraction (24\% {\textpm} 3\% to 35\% {\textpm} 4\%, p = 0.015).Conclusion: PAH-approved drug treatment improves RV dilatation and systolic function in patients with severe group 3 PH.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/46/suppl_59/PA3767}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }